CN113564078A - Bifidobacterium lactis BLA80 for reducing cholesterol and application thereof - Google Patents
Bifidobacterium lactis BLA80 for reducing cholesterol and application thereof Download PDFInfo
- Publication number
- CN113564078A CN113564078A CN202110864979.7A CN202110864979A CN113564078A CN 113564078 A CN113564078 A CN 113564078A CN 202110864979 A CN202110864979 A CN 202110864979A CN 113564078 A CN113564078 A CN 113564078A
- Authority
- CN
- China
- Prior art keywords
- bifidobacterium lactis
- bla80
- cholesterol
- lactis
- bifidobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 title claims abstract description 72
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 title claims abstract description 56
- 229940009289 bifidobacterium lactis Drugs 0.000 title claims abstract description 54
- 235000012000 cholesterol Nutrition 0.000 title claims abstract description 32
- 239000007787 solid Substances 0.000 claims abstract description 8
- 239000003814 drug Substances 0.000 claims abstract description 6
- 238000004321 preservation Methods 0.000 claims abstract description 6
- 235000013361 beverage Nutrition 0.000 claims abstract description 5
- 235000013402 health food Nutrition 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 2
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 244000052616 bacterial pathogen Species 0.000 abstract description 8
- 230000003115 biocidal effect Effects 0.000 abstract description 7
- 235000011389 fruit/vegetable juice Nutrition 0.000 abstract description 7
- 239000006041 probiotic Substances 0.000 abstract description 7
- 235000018291 probiotics Nutrition 0.000 abstract description 7
- 108010000231 Choloylglycine hydrolase Proteins 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 244000005700 microbiome Species 0.000 abstract description 5
- 235000013305 food Nutrition 0.000 abstract description 4
- 210000004211 gastric acid Anatomy 0.000 abstract description 3
- 230000000529 probiotic effect Effects 0.000 abstract description 3
- 239000001963 growth medium Substances 0.000 description 10
- 230000001580 bacterial effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000001556 precipitation Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 108010023302 HDL Cholesterol Proteins 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 230000001954 sterilising effect Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000009630 liquid culture Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 241000191967 Staphylococcus aureus Species 0.000 description 3
- 230000003042 antagnostic effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical group CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108010059993 Vancomycin Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229960003022 amoxicillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960004099 azithromycin Drugs 0.000 description 2
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 229960005361 cefaclor Drugs 0.000 description 2
- QYIYFLOTGYLRGG-GPCCPHFNSA-N cefaclor Chemical compound C1([C@H](C(=O)N[C@@H]2C(N3C(=C(Cl)CS[C@@H]32)C(O)=O)=O)N)=CC=CC=C1 QYIYFLOTGYLRGG-GPCCPHFNSA-N 0.000 description 2
- 229960004755 ceftriaxone Drugs 0.000 description 2
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 2
- 229960002227 clindamycin Drugs 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960003276 erythromycin Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940054441 o-phthalaldehyde Drugs 0.000 description 2
- UWYHMGVUTGAWSP-JKIFEVAISA-N oxacillin Chemical compound N([C@@H]1C(N2[C@H](C(C)(C)S[C@@H]21)C(O)=O)=O)C(=O)C1=C(C)ON=C1C1=CC=CC=C1 UWYHMGVUTGAWSP-JKIFEVAISA-N 0.000 description 2
- 229960001019 oxacillin Drugs 0.000 description 2
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 2
- 229960001225 rifampicin Drugs 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- GNBVPFITFYNRCN-UHFFFAOYSA-M sodium thioglycolate Chemical compound [Na+].[O-]C(=O)CS GNBVPFITFYNRCN-UHFFFAOYSA-M 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 229960003165 vancomycin Drugs 0.000 description 2
- MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 2
- MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 2
- 235000020927 12-h fasting Nutrition 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- YLZYSVYZMDJYOT-UHFFFAOYSA-N 2-methoxypyrimidine Chemical compound COC1=NC=CC=N1 YLZYSVYZMDJYOT-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- YJQPYGGHQPGBLI-UHFFFAOYSA-N Novobiocin Natural products O1C(C)(C)C(OC)C(OC(N)=O)C(O)C1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-UHFFFAOYSA-N 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- VLSOAXRVHARBEQ-UHFFFAOYSA-N [4-fluoro-2-(hydroxymethyl)phenyl]methanol Chemical compound OCC1=CC=C(F)C=C1CO VLSOAXRVHARBEQ-UHFFFAOYSA-N 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 229940040526 anhydrous sodium acetate Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- KLOIYEQEVSIOOO-UHFFFAOYSA-N carbocromen Chemical compound CC1=C(CCN(CC)CC)C(=O)OC2=CC(OCC(=O)OCC)=CC=C21 KLOIYEQEVSIOOO-UHFFFAOYSA-N 0.000 description 1
- 229960000603 cefalotin Drugs 0.000 description 1
- VUFGUVLLDPOSBC-XRZFDKQNSA-M cephalothin sodium Chemical compound [Na+].N([C@H]1[C@@H]2N(C1=O)C(=C(CS2)COC(=O)C)C([O-])=O)C(=O)CC1=CC=CS1 VUFGUVLLDPOSBC-XRZFDKQNSA-M 0.000 description 1
- -1 cephamine Chemical compound 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000015140 cultured milk Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000000369 enteropathogenic effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 229910052564 epsomite Inorganic materials 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000010565 inoculated fermentation Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 229910000357 manganese(II) sulfate Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960002950 novobiocin Drugs 0.000 description 1
- YJQPYGGHQPGBLI-KGSXXDOSSA-N novobiocin Chemical compound O1C(C)(C)[C@H](OC)[C@@H](OC(N)=O)[C@@H](O)[C@@H]1OC1=CC=C(C(O)=C(NC(=O)C=2C=C(CC=C(C)C)C(O)=CC=2)C(=O)O2)C2=C1C YJQPYGGHQPGBLI-KGSXXDOSSA-N 0.000 description 1
- 229940078552 o-xylene Drugs 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 229940046307 sodium thioglycolate Drugs 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- AWDRATDZQPNJFN-VAYUFCLWSA-N taurodeoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 AWDRATDZQPNJFN-VAYUFCLWSA-N 0.000 description 1
- IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
- 229960001082 trimethoprim Drugs 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/515—Animalis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a bifidobacterium lactis BLA80 for reducing cholesterol and application thereof, belonging to the technical field of microorganisms. The bifidobacterium lactis BLA80 is preserved in the common microorganism center of China Committee for culture Collection of microorganisms with the preservation number of CGMCC No. 22547. The bifidobacterium lactis BLA80 has strong gastric acid resistance and intestinal juice resistance, has strong inhibiting effect on common intestinal pathogenic bacteria, has no antibiotic resistance and is safe probiotic. The bifidobacterium lactis BLA80 has strong activity of bile salt hydrolase and excellent cholesterol-lowering property, the cholesterol removal rate can reach 92.4 percent, the content of serum cholesterol can be obviously lowered, and the bifidobacterium lactis BLA80 can be used for preparing medicaments or foods such as cholesterol-lowering medicinal health-care foods or solid beverages.
Description
Technical Field
The invention belongs to the technical field of microorganisms, and particularly relates to a bifidobacterium lactis BLA80 for reducing cholesterol and application thereof.
Background
Probiotics are defined as living microorganisms that are beneficial to the health of the host when taken in appropriate doses. The bifidobacterium and the lactobacillus are common probiotics in human intestinal tracts, have the effects of improving intestinal micro-ecology, inhibiting the growth of intestinal pathogenic bacteria, reducing serum cholesterol, improving the immunity of organisms and the like, and play a vital role in human health.
Hypercholesterolemia is one of the most main factors causing cardiovascular diseases such as coronary heart disease, hypertension, atherosclerosis and the like, and the morbidity and the mortality rate are in a trend of rising year by year. The reduction of serum cholesterol level is related to human health, and as the health consciousness of people in China is improved, more and more people tend to realize the health by improving diet, eating probiotics and the like instead of drug therapy. Therefore, it is a research focus in recent years to explore the cholesterol lowering properties of probiotics.
Disclosure of Invention
The invention aims to provide a bifidobacterium lactis strain with cholesterol-lowering property and application thereof.
The purpose of the invention is realized by the following technical scheme:
a Bifidobacterium lactis strain with cholesterol lowering property is Bifidobacterium lactis BLA80 with the preservation number of CGMCC No.22547, and is classified and named as follows: bifidobacterium animalis subsp. lactis, preservation time: 2021, 05 month, 17 days; the preservation unit: china general microbiological culture Collection center; and (4) storage address: xilu No. 1 Hospital No. 3, Beijing, Chaoyang, North.
The bifidobacterium lactis BLA80 has strong bile salt hydrolase activity and excellent cholesterol-lowering property, can obviously reduce the content of serum cholesterol, and can be used for preparing medicaments and foods for lowering cholesterol, such as health-care foods or solid beverages and the like.
A medicine, health food and solid beverage for reducing cholesterol comprise Bifidobacterium lactis BLA 80.
The bifidobacterium lactis BLa80 also has the following characteristics:
(1) can resist gastrointestinal tract environment, and has strong gastric acid resistance and intestinal juice resistance.
(2) Has strong capability of inhibiting pathogenic bacteria, and has strong bacteriostatic capability on escherichia coli, salmonella and staphylococcus aureus.
(3) The antibiotic-free compound preparation is sensitive to 15 common antibiotics of erythromycin, penicillin, amoxicillin, ampicillin, vancomycin, cefaclor, oxacillin, ceftriaxone, neomycin, cephalothin, clindamycin, azithromycin, methoxypyrimidine and rifampicin, has no antibiotic resistance and is high in safety.
Compared with the prior art, the invention has the following advantages and beneficial effects: the bifidobacterium lactis BLA80 has strong gastric acid resistance and intestinal juice resistance, has strong inhibiting effect on common intestinal pathogenic bacteria, has no antibiotic resistance, and is safe probiotic. The bifidobacterium lactis BLA80 has excellent cholesterol-lowering property and can remarkably lower the content of serum cholesterol.
Drawings
FIG. 1 shows the colony formed by Bifidobacterium lactis.
Detailed Description
The following description of the embodiments of the present invention is provided for illustrative purposes, and other advantages and effects of the present invention will become apparent to those skilled in the art from the present disclosure.
The following examples are intended to illustrate the invention but are not intended to limit the scope of the invention.
Example 1 Bifidobacterium lactis screening with bile salt hydrolase Activity
11 different strains of Bifidobacterium lactis were isolated from healthy infants and breast milk samples, and Bifidobacterium lactis having high bile salt hydrolase activity was selected from these strains.
Strain activation: taking out the glycerol tube from a refrigerator at minus 80 ℃, unfreezing, inoculating the glycerol tube into an anaerobic tube filled with an L-MRS culture medium in an inoculation amount of 2%, culturing for 12-24 h at 37 ℃, and growing until the bacterial liquid is turbid to be an activated generation.
The components of the L-MRS culture medium are as follows: by mass percentage, 2.0 percent of glucose, 0.5 percent of yeast extract powder, 1.0 percent of peptone, 1.0 percent of beef extract powder, 0.5 percent of anhydrous sodium acetate, 800.1 percent of tween, 0.2 percent of diammonium hydrogen citrate, 0.2 percent of dipotassium hydrogen phosphate and MgSO4·7H2O 0.06％、MnSO40.02%, 0.1% L-cysteine hydrochloride, an initial pH value of 7.0 +/-0.1, and sterilizing at 118 ℃ for 30min for later use.
Adding 0.37g/L CaCI into freshly prepared MRS liquid culture medium25g/L taurodeoxycholic acid and 15g/L agar, sterilizing at 121 ℃ for 15min, taking out, cooling to 40-50 ℃, pouring on a flat plate with an Oxford cup, and carefully taking out the Oxford cup after the culture medium is completely solidified. And inoculating 100 mu L of activated bacterial liquid on a flat plate, carrying out anaerobic culture at 37 ℃ for 48h, observing whether a precipitation ring is formed around the bacterial lawn, wherein if white precipitates are formed, the bile salt hydrolase activity is shown, and the bigger the diameter of the precipitation ring is, the stronger the bile salt hydrolase activity is shown.
The experimental results are as follows: the size of the precipitation circle of the 11 isolated strains of bifidobacterium lactis is shown in table 1, wherein the precipitation circles of the S01, S03 and S09 strains are shown in fig. 1.
TABLE 1 Bifidobacterium lactis precipitation ring size (mm)
As is clear from Table 1, 5 strains S01, S02, S07, S09 and S10 having larger diameters of the colony were selected by comparing the diameters of the colony, and the cholesterol removal rate was measured.
EXAMPLE 2 Cholesterol removal Rate determination
According to the diameter of the precipitation ring, 5 strains of bifidobacterium lactis are selected for measuring the cholesterol removal rate.
(1) Cholesterol standard curve determination: accurately weighing 0.1g of cholesterol powder, metering the volume of a solution of 1mg/mL by using n-hexane, then respectively sucking 0.02 mL, 0.04 mL, 0.06 mL, 0.08 mL, 0.1 mL, 0.12 mL and 0.14mL into a colorimetric tube, drying by using water bath nitrogen at 60 ℃, adding 4mL of 0.5mg/mL o-phthalaldehyde solution and 2mL of 98% concentrated sulfuric acid, carrying out color development reaction for 20min, measuring the absorbance value at 553nm, and taking the cholesterol content as the horizontal axis and the absorbance value as the vertical axis as a standard curve.
(2) The method for measuring the cholesterol content by o-xylene comprises the following steps: 1mL of sample was added with 3mL of 95% ethanol and 2mL of 50% (w/v) potassium hydroxide, and vortexed and mixed. And (3) carrying out constant-temperature water bath at 60 ℃ for 10min, cooling, adding 5mL of n-hexane, carrying out vortex oscillation extraction for 1-2min, adding 2mL of distilled water, oscillating uniformly, and standing for layering. Taking 2mL of upper-layer n-hexane, drying the upper-layer n-hexane by blowing with nitrogen in a water bath at 60 ℃, adding 4mL of 0.5mg/mL (w/v) o-dicarbaldehyde solution (constant volume by glacial acetic acid) and 2mL of concentrated sulfuric acid, carrying out color reaction for 20min, and measuring the absorbance value at 553 nm.
(3) Determination of cholesterol removal rate of bifidobacterium lactis:
inoculating the strain into an anaerobic tube filled with L-MRS liquid culture medium, standing and culturing at 37 ℃ for 12h, transferring for 3 times of activation, inoculating into 5mL of culture solution MRSO-CHOL according to the inoculation amount of 2% (v/v), shaking uniformly, immediately sampling for 1mL, centrifuging for 5min at 4000r/min, and taking the supernatant to measure the cholesterol content by using an o-phthalaldehyde colorimetric method. After the inoculated fermentation liquor is statically cultured for 48 hours at 37 ℃, the cholesterol content in the supernatant is measured by the same method, and a plurality of groups of parallel averages are made. Wherein the composition of the culture solution MRSO-CHOL is as follows: consists of MRS liquid culture medium, sodium thioglycollate, cholesterol and ox bile salt; the concentration of sodium thioglycolate is 2g/L, the concentration of cholesterol is 200mg/L, the concentration of the ox bile salt is 0.3% (mass fraction), and the sterilization is carried out for 20min at 115 ℃.
Removal rate of cholesterol:
in the formula: a is the absorbance value at 553nm of the culture medium after fermentation of each strain, and B is the absorbance value at 553nm of the blank control.
(4) Results of Bifidobacterium lactis Cholesterol removal Rate
TABLE 2 Bifidobacterium lactis cholesterol removal rate
As can be seen from Table 2, S09 showed the best removal rate of cholesterol, which was 92.4%, and was selected as the strain to be tested.
Example 3 molecular biological identification of Bifidobacterium lactis
S09 cells are cultured and collected, named Bla80 again, strain genome DNA is extracted by a genome DNA extraction kit (TIANGEN company), and a 16S rDNA sequence is amplified by an upstream primer 27F (AGTTTGATCTMTGGCTCAG) and a downstream primer 1492R (GGTTACCTTGTTACGACTT) to obtain a PCR product. And sequencing the PCR product. Wherein the PCR reaction system comprises: 10 XBuffer 20. mu.L, primer dNTP 4. mu.L, upstream and downstream primers 1. mu.L each, DNA template 2. mu.L, Taq enzyme 0.5. mu.L, ddH2O 34.5.5. mu.L. And (3) PCR reaction conditions: 10min at 95 ℃; 30s at 94 ℃, 30s at 56 ℃, 2min at 72 ℃ and 35 cycles; 10min at 72 ℃. And (3) detecting the PCR product through gel electrophoresis, and then sending the PCR product to Wuhan Jinrui bioengineering company Limited for sequencing. The measured gene sequences were submitted to the NCBI database (www.ncbi.nlm.nih.gov) for BLAST analysis alignment. Through the above identification results, the strain BLa80, named as Bifidobacterium lactis, was identified as Bifidobacterium animalis subsp. lactis, and was deposited in the common microorganism center of the committee for culture collection of microorganisms china at 17 th 2021, CGMCC for short, address: no. 3 of Xilu No. 1 of Beijing, Chaoyang, and the preservation number is CGMCC No. 22547.
Example 4 environmental assessment of Bifidobacterium lactis BLA80 by gastrointestinal tract
Simulated artificial gastric fluid: preparing 0.5% NaCl solution, adding 0.3% pepsin, adjusting pH to 2.5 with 1mol/L HCL, fully dissolving, and filtering with 0.22 μm microporous membrane for sterilization.
Simulating artificial intestinal juice: preparing 0.5% NaCl solution, adding 0.1% trypsin, adjusting pH to 8.0 with 0.1mol/L NaOH, dissolving completely, filtering with 0.22 μm microporous membrane, and sterilizing.
Bifidobacterium lactis BLa80 was activated and cultured for 2 passages under anaerobic conditions. And (3) centrifuging the activated bifidobacterium lactis BLA80 bacterial liquid, and collecting the bacterial cells. 0.4mL of the thallus suspension is respectively inoculated into 1.6mL of prepared simulated artificial gastric juice with the pH value of 2.5 and simulated artificial intestinal juice with the pH value of 8.0 to be mixed uniformly, the mixture is digested at the temperature of 37 ℃, meanwhile, 0h and 3h of digestive juice are respectively taken to detect the viable count, the survival rate is calculated, and the result is shown in a table 3. Wherein, the survival rate of the strain is N%t/N0X 100%, wherein N0 represents the viable cell count (CFU/mL) of 0h, and NtThe number of viable bacteria of strain 3h (CFU/mL) was indicated.
TABLE 3 Experimental data sheet for Bifidobacterium lactis BLA80 simulated digestive tract environment
The results in Table 3 show that Bifidobacterium lactis Bla80 has a survival rate of 96.7% in artificial gastric juice at pH2.5 for 3 hours and 93.6% in artificial intestinal juice at pH8.0 for 3 hours. Experiments show that the bifidobacterium lactis BLA80 has strong capability of tolerating the environment of the gastrointestinal tract.
Example 5 evaluation of bacteriostatic Activity of Bifidobacterium lactis BLA80
Inoculating antagonistic strain into an anaerobic glass tube of L-MRS liquid culture medium according to 2% (V/V), and standing and culturing at constant temperature of 37 ℃ for 12 h. Respectively inoculating pathogenic strains of Escherichia coli, salmonella and Staphylococcus aureus into liquid beef extract peptone medium, culturing at 37 deg.C and 250rpm with constant temperature shaking table overnight, and preparing pathogenic bacteria suspension. Cooling MRS solid culture medium to about 55 deg.C, mixing with the pathogenic bacteria suspension at a certain ratio to make the number of live bacteria in system pathogenic bacteria be 106CFU/mL order of magnitude, quickly pouring into a plate with an Oxford cup in advance, taking out the Oxford cup after the culture medium is cooled and solidified, injecting 200 mu L of antagonistic strain liquid into each hole, slightly covering the plate, placing the plate in a constant-temperature incubator at 37 ℃, culturing for a proper time, observing, and using a vernier caliperThe diameter of the zone of inhibition was measured with a ruler and the results are shown in Table 4.
TABLE 4 antagonistic activity of Bifidobacterium lactis BLA80 against pathogenic bacteria data Table
The results in table 4 show that bifidobacterium lactis BLa80 has strong inhibitory effect on common enteropathogenic bacteria of escherichia coli, salmonella and staphylococcus aureus, especially on escherichia coli and salmonella.
Example 6 evaluation of antibiotic susceptibility of Bifidobacterium lactis BLA80
Marking and activating bacteria to be detected on an L-MRS solid plate, preparing a bacterial suspension and adjusting the concentration of the bacterial suspension to be 108CFU/mL, 100. mu.L of the bacterial suspension is added on an L-MRS solid plate, the bacterial liquid is uniformly coated on the plate by using a sterile cotton swab, and an antibiotic drug sensitive sheet is attached, and a paper sheet without antibiotic is used as a blank control. The strain was cultured in an anaerobic condition at 37 ℃ in an upright manner, and after 24 hours, the antibiotic-sensitive diameter of the strain was measured with a ruler, and the results are shown in Table 5.
TABLE 5 Bifidobacterium lactis BLA80 sensitivity data to antibiotics (mm)
The results in table 5 show that bifidobacterium lactis BLa80 is highly sensitive to the 14 antibiotics erythromycin, penicillin, amoxicillin, ampicillin, vancomycin, cefaclor, oxacillin, ceftriaxone, novobiocin, cephamine, clindamycin, azithromycin rifampicin and trimethoprim evaluated, the zone diameters are all greater than 20mm, and the zone diameters for 10 of these antibiotics are greater than 30 mm. Experiments show that bifidobacterium lactis BLa80 is a safe probiotic.
Example 7 Bifidobacterium lactis BLA80 ability to reduce serum cholesterol in mice
(1) Experimental grouping and feeding mode
Collecting cultured milk bifidobacteriaThe strain BLA80 was washed 3 times with physiological saline to adjust the concentration to 1.0X 109CFU/mL was used for mouse gavage. 30 8-week-old BALB/c mice were reclassified into 3 groups with no significant difference in mean body mass between groups: normal group: basal feed was fed, control group: feeding high-fat feed and physiological saline, and performing experiment groups: high fat diet + strain BLa80 was fed, 10 per group. Each mouse was gavaged for 1 mL/day for 14 days.
(2) Determination of TC, TG and HDL-C content in serum
And (4) fasting for 12h at 14d after gastric lavage of the mice, respectively collecting blood, centrifuging for 10min at 2500r/min, and taking serum. And respectively referring to the kit for description, measuring the contents of TC, TG and HDL-C in the serum by using an enzyme-labeling instrument, and comparing the difference of serum indexes among groups.
(3) Data processing
Significance was tested by analysis of variance using SPSS 26 statistical software, and data analysis was performed by Least Significant Difference (LSD) test for multiple comparisons.
(4) Analysis of results of Bifidobacterium lactis BLA80 on reduction of serum cholesterol in mice
TABLE 6 Effect of Bifidobacterium lactis BLA80 on mouse serum TC, TG, HDL-C (mmol/L)
Note: different letters in the same column indicate significant differences (P < 0.05).
As can be seen from table 6, when the mice were fed with the high-fat diet for 14 days, the serum TC levels of the mice in the control group and the experimental group were both significantly increased, and the levels of the mice in the experimental group were significantly decreased compared to the control group; the content of serum TG in the experimental group has no significant difference with that of the control group, and the level of the control group is significantly increased; the serum HDL-C levels of the control and experimental groups were significantly higher than those of the normal group, while the difference between the two groups was not significant. The TC, TG and HDL-C in the serum of the mice in the experimental group which eat the bifidobacterium lactis BLA80 are respectively reduced by 24.3%, 20.3% and 9.2% compared with the control group, which indicates that the bifidobacterium lactis BLA80 can obviously reduce the serum cholesterol level of the mice.
Claims (7)
1. A strain of Bifidobacterium lactis (Lactobacillus lactis) having cholesterol lowering properties, characterized in that: is Bifidobacterium lactis BLA80 with the preservation number of CGMCC No. 22547.
2. Use of a bifidobacterium lactis as claimed in claim 1 in the manufacture of a medicament for use in lowering cholesterol.
3. A drug for reducing cholesterol, which is characterized in that: comprising bifidobacterium lactis BLa80 as claimed in claim 1.
4. Use of bifidobacterium lactis as claimed in claim 1 in the preparation of a health food for lowering cholesterol.
5. A health food for reducing cholesterol is characterized in that: comprising bifidobacterium lactis BLa80 as claimed in claim 1.
6. Use of bifidobacterium lactis as claimed in claim 1 for the preparation of a solid beverage for lowering cholesterol.
7. A solid beverage for reducing cholesterol is characterized in that: comprising bifidobacterium lactis BLa80 as claimed in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110864979.7A CN113564078B (en) | 2021-07-29 | 2021-07-29 | Bifidobacterium lactis BLa80 for reducing cholesterol and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110864979.7A CN113564078B (en) | 2021-07-29 | 2021-07-29 | Bifidobacterium lactis BLa80 for reducing cholesterol and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113564078A true CN113564078A (en) | 2021-10-29 |
| CN113564078B CN113564078B (en) | 2023-10-20 |
Family
ID=78169094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110864979.7A Active CN113564078B (en) | 2021-07-29 | 2021-07-29 | Bifidobacterium lactis BLa80 for reducing cholesterol and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113564078B (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113913322A (en) * | 2021-08-25 | 2022-01-11 | 微康益生菌(苏州)股份有限公司 | Application of bifidobacterium lactis BLA80 in relieving diarrhea and improving intestinal immunity |
| CN113913352A (en) * | 2021-11-29 | 2022-01-11 | 微康益生菌(苏州)股份有限公司 | Streptococcus thermophilus capable of producing extracellular exopolysaccharide and culture method and application thereof |
| CN114480229A (en) * | 2022-04-15 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis strain WKB148 and product and application thereof |
| CN114574407A (en) * | 2022-05-06 | 2022-06-03 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis WKB99, and application and product thereof in preparation of product for improving metabolic syndrome |
| CN115119940A (en) * | 2021-12-23 | 2022-09-30 | 微康益生菌(苏州)股份有限公司 | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori |
| CN117757693A (en) * | 2023-12-30 | 2024-03-26 | 镇江市远胜生物工程有限公司 | Bifidobacterium lactis BL-H4P capable of reducing cholesterol and resisting gastric acid and intestinal juice, and domestication fermentation method, microbial inoculum and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103648512A (en) * | 2011-05-09 | 2014-03-19 | 益生菌股份公司 | Bacterial strains belonging to the genus bifidobacterium for use in the treatment of hypercholesterolaemia |
| CN104531590A (en) * | 2015-01-14 | 2015-04-22 | 贵州大学 | Fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll |
| CN104560829A (en) * | 2015-01-14 | 2015-04-29 | 贵州大学 | Fragrance pig source cholesterol-reducing and oxygen-resistant bifidobacterium BZ25 |
| CN113088465A (en) * | 2021-04-02 | 2021-07-09 | 湖北均瑶大健康饮品股份有限公司 | Bifidobacterium lactis strain J605 and application thereof |
-
2021
- 2021-07-29 CN CN202110864979.7A patent/CN113564078B/en active Active
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103648512A (en) * | 2011-05-09 | 2014-03-19 | 益生菌股份公司 | Bacterial strains belonging to the genus bifidobacterium for use in the treatment of hypercholesterolaemia |
| CN104531590A (en) * | 2015-01-14 | 2015-04-22 | 贵州大学 | Fragrant pig derived cholesterol-assimilating and oxygen-resistant bifidobacterium BZll |
| CN104560829A (en) * | 2015-01-14 | 2015-04-29 | 贵州大学 | Fragrance pig source cholesterol-reducing and oxygen-resistant bifidobacterium BZ25 |
| CN113088465A (en) * | 2021-04-02 | 2021-07-09 | 湖北均瑶大健康饮品股份有限公司 | Bifidobacterium lactis strain J605 and application thereof |
Non-Patent Citations (5)
| Title |
|---|
| 阿里巴巴1688平台: "微康益生菌乳双歧杆菌BLa80高活性高稳定益生菌菌种", 《HTTPS://WWW.1688.COM/CHANPIN/-B9D1CCC7D2E6C9FABEFA.HTML》 * |
| 阿里巴巴1688平台: "微康益生菌乳双歧杆菌BLa80高活性高稳定益生菌菌种", 《HTTPS://WWW.1688.COM/CHANPIN/-B9D1CCC7D2E6C9FABEFA.HTML》, 15 February 2019 (2019-02-15), pages 1 * |
| 陈珂可等: "具有降解胆固醇能力的益生菌菌株筛选", 《食品科技》 * |
| 陈珂可等: "具有降解胆固醇能力的益生菌菌株筛选", 《食品科技》, vol. 43, no. 11, 31 December 2018 (2018-12-31), pages 9 * |
| 韦云路: "3 株益生菌体外降胆固醇能力及体内降血脂效果评价", 《食品科学》, vol. 38, no. 23, pages 129 - 134 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113913322A (en) * | 2021-08-25 | 2022-01-11 | 微康益生菌(苏州)股份有限公司 | Application of bifidobacterium lactis BLA80 in relieving diarrhea and improving intestinal immunity |
| CN113913352A (en) * | 2021-11-29 | 2022-01-11 | 微康益生菌(苏州)股份有限公司 | Streptococcus thermophilus capable of producing extracellular exopolysaccharide and culture method and application thereof |
| CN115119940A (en) * | 2021-12-23 | 2022-09-30 | 微康益生菌(苏州)股份有限公司 | Application of Lactobacillus acidophilus LA85 and Bifidobacterium lactis BLA80 in inhibiting helicobacter pylori |
| CN114480229A (en) * | 2022-04-15 | 2022-05-13 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis strain WKB148 and product and application thereof |
| CN114574407A (en) * | 2022-05-06 | 2022-06-03 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis WKB99, and application and product thereof in preparation of product for improving metabolic syndrome |
| CN114574407B (en) * | 2022-05-06 | 2022-11-01 | 微康益生菌(苏州)股份有限公司 | Bifidobacterium animalis subsp lactis WKB99 and application thereof in preparation of product for improving metabolic syndrome and product |
| CN117757693A (en) * | 2023-12-30 | 2024-03-26 | 镇江市远胜生物工程有限公司 | Bifidobacterium lactis BL-H4P capable of reducing cholesterol and resisting gastric acid and intestinal juice, and domestication fermentation method, microbial inoculum and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113564078B (en) | 2023-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113564078B (en) | Bifidobacterium lactis BLa80 for reducing cholesterol and application thereof | |
| CN111235070B (en) | Breast milk infant source lactobacillus plantarum BF _15 and application thereof | |
| CN113088465B (en) | Bifidobacterium lactis strain J605 and application thereof | |
| CN113832058A (en) | Application of bifidobacterium lactis BLA80 in preparation of medicines or foods for reducing blood fat and regulating intestinal flora | |
| WO2021114658A1 (en) | Bifidobacterium animalis subsp. lactis i797, method for separation and purification thereof, and use thereof | |
| CN110144304B (en) | Lactobacillus casei strain and application thereof | |
| CN107523514B (en) | Extracellular polysaccharide-producing lactobacillus plantarum capable of effectively adsorbing phthalic acid monoester | |
| CN113913322B (en) | Application of bifidobacterium lactis BLA80 in relieving diarrhea and improving intestinal immunity | |
| CN110628663B (en) | Lactobacillus rhamnosus and high-density culture method and application thereof | |
| CN116024130B (en) | Lactobacillus fermentum A21215 for reducing blood uric acid and application thereof | |
| CN113293118B (en) | Lactobacillus rhamnosus LR3001 and application thereof | |
| CN113122467B (en) | Lactobacillus paracasei and composition thereof | |
| CN110023486B (en) | Lactobacillus acidophilus and culture method and application thereof | |
| CN115851500B (en) | Lactobacillus plantarum and application thereof | |
| CN106434489B (en) | High-yield wine Klebsiella pneumoniae strain and application thereof | |
| CN109983115B (en) | Lactobacillus gasseri and culture method and application thereof | |
| CN114774315A (en) | Application of lactobacillus rhamnosus strain LRa05 in preparing immunity enhancing and/or eczema relieving product | |
| CN113151070A (en) | Lactobacillus fermentum capable of improving relative abundance of Guttiferae in intestinal tract | |
| CN116445356B (en) | Bifidobacterium animalis subspecies BA67 for regulating intestinal flora and enhancing immunity and application thereof | |
| CN113913334B (en) | Enterococcus faecalis EF-ZA1107-06 and application thereof | |
| CN111004735A (en) | Lactobacillus fermentum and application thereof in improving intestinal health | |
| CN112980737B (en) | Bifidobacterium adolescentis for promoting proliferation of animal bifidobacterium and application thereof | |
| CN109161501B (en) | Feeding bacillus licheniformis and application thereof | |
| CN116590181B (en) | Lactobacillus paracasei for improving inflammatory reaction caused by microplastic pollution and application thereof | |
| RU2184146C1 (en) | Bifidobacterium bifidum 45 vkpm ac-1621 strain used to produce bacterial preparations and food products |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |